{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:29:57Z","timestamp":1794508197643,"version":"4.9.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1097\/01.jcp.0000095342.32154.54","type":"journal-article","created":{"date-parts":[[2003,11,18]],"date-time":"2003-11-18T07:31:58Z","timestamp":1069140718000},"page":"568-575","source":"Crossref","is-referenced-by-count":113,"title":["A Double Blind Comparison of Venlafaxine and Paroxetine in Obsessive-Compulsive Disorder"],"prefix":"10.1097","volume":"23","author":[{"given":"Damiaan","family":"Denys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nic","family":"van der Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold J.G.M.","family":"van Megen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman G.M.","family":"Westenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210128","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1001\/archpsyc.1991.01810320054008","article-title":"Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group [see comments]","volume":"48","author":"DeVeaugh-Geiss","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"R2-7-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00004850-199603000-00003","article-title":"Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.","volume":"11","author":"Goodman","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"R3-7-20210128","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/archpsyc.1994.03950070051010","article-title":"A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder.","volume":"51","author":"Tollefson","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"R4-7-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004850-199506000-00001","article-title":"A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder.","volume":"10","author":"Greist","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"key":"R5-7-20210128","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1192\/bjp.169.4.468","article-title":"Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators.","volume":"169","author":"Zohar","year":"1996","journal-title":"Br J Psychiatry"},{"key":"R6-7-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004850-200103000-00002","article-title":"Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder.","volume":"16","author":"Montgomery","year":"2001","journal-title":"Int Clin Psychopharmacol"},{"key":"R7-7-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004850-199503000-00002","article-title":"Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder.","volume":"10","author":"Stein","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"key":"R8-7-20210128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/archpsyc.1995.03950130053006","article-title":"Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.","volume":"52","author":"Greist","year":"1995","journal-title":"Arch Gen Psychiatry"},{"key":"R9-7-20210128","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1192\/bjp.166.4.424","article-title":"Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.","volume":"166","author":"Piccinelli","year":"1995","journal-title":"Br J Psychiatry"},{"key":"R10-7-20210128","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00004714-200206000-00012","article-title":"Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder.","volume":"22","author":"Ackerman","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"R11-7-20210128","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/1520-6394(2000)12:1+<20::AID-DA3>3.0.CO;2-M","article-title":"Neuropharmacology of venlafaxine.","volume":"12","author":"Roseboom","year":"2000","journal-title":"Depress Anxiety"},{"key":"R12-7-20210128","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/archpsyc.57.5.503","article-title":"Evidence of the dual mechanisms of action of venlafaxine.","volume":"57","author":"Harvey","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R13-7-20210128","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1176\/ajp.152.12.1832a","article-title":"Venlafaxine for treatment of obsessive-compulsive disorder [letter].","volume":"152","author":"Ananth","year":"1995","journal-title":"Am J Psychiatry"},{"key":"R14-7-20210128","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1176\/ajp.153.4.576b","article-title":"Treatment of obsessive-compulsive disorder with venlafaxine.","volume":"153","author":"Grossman","year":"1996","journal-title":"Am J Psychiatry"},{"key":"R15-7-20210128","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00004714-199004000-00033","article-title":"Coexisting major depression and obsessive-compulsive disorder treated with venlafaxine.","volume":"10","author":"Zajecka","year":"1990","journal-title":"J Clin Psychopharmacol"},{"key":"R16-7-20210128","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00004714-199602000-00017","article-title":"Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases.","volume":"16","author":"Rauch","year":"1996","journal-title":"J Clin Psychopharmacol"},{"key":"R17-7-20210128","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1001\/archpsyc.1996.01830070103016","article-title":"Venlafaxine in obsessive-compulsive disorder.","volume":"53","author":"Yaryura-Tobias","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"R18-7-20210128","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview forDSM-IVandICD-10.","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R19-7-20210128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression.","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R20-7-20210128","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1600-0447.1992.tb10326.x","article-title":"The interrater reliability of a Dutch version of the Structured Clinical Interview forDSM-III-RPersonality Disorders.","volume":"85","author":"Arntz","year":"1992","journal-title":"Acta Psychiatr Scand"},{"key":"R21-7-20210128","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"R22-7-20210128","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating.","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br J Med Psychol"},{"key":"R23-7-20210128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0378-4347(01)00305-X","article-title":"High-performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum.","volume":"761","author":"Tournel","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R24-7-20210128","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/0005-7967(95)00014-O","article-title":"Factor structure of the Yale-Brown Obsessive-Compulsive Scale: a two dimensional measure.","volume":"33","author":"McKay","year":"1995","journal-title":"Behav Res Ther"},{"key":"R25-7-20210128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0005-7967(98)00134-X","article-title":"Symptom structure in obsessive-compulsive disorder: a confirmatory factor-analytic study.","volume":"37","author":"Summerfeldt","year":"1999","journal-title":"Behav Res Ther"},{"key":"R26-7-20210128","doi-asserted-by":"crossref","first-page":"54S","DOI":"10.1097\/00004714-199606002-00011","article-title":"The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database.","volume":"16","author":"Rudolph","year":"1996","journal-title":"J Clin Psychopharmacol"},{"key":"R27-7-20210128","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s002130051106","article-title":"Acute effects of venlafaxine and paroxetine on serotonergic transmission in human volunteers.","volume":"146","author":"Porter","year":"1999","journal-title":"Psychopharmacology Berl"},{"key":"R28-7-20210128","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0006-3223(91)90107-W","article-title":"Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder.","volume":"30","author":"Austin","year":"1991","journal-title":"Biol Psychiatry"},{"key":"R29-7-20210128","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archpsyc.1995.03950160039008","article-title":"Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder.","volume":"52","author":"Greist","year":"1995","journal-title":"Arch Gen Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.jcp.0000095342.32154.54","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:44:24Z","timestamp":1785768264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-200312000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jcp.0000095342.32154.54","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}